- ISIN
- KYG9TY5A1016
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Sep 3, 2021
Highlights
- Market Cap
- $474.70M
- Enterprise Value
- $249.11M
- EPS (TTM)
- -$1.07
- Gross Profit (TTM)
- -$29.00K
- EBITDA (TTM)
- -$79.99M
- Year Range
- $1.00 - $7.44
- Target Price
- $15.00
- ROA (TTM)
- -46.42%
- ROE (TTM)
- -48.93%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZURA Performance Chart
Zura Bio Limited (ZURA) is down 19.3% since the beginning of the year. At $4 per share, ZURA is trading 43.1% below its 52-week high of $7.
Loading charts...
Returns By Period
Zura Bio Limited (ZURA) has returned -19.27% so far this year and 274.34% over the past 12 months.
Zura Bio Limited
- 1D
- 12.80%
- 1M
- -2.98%
- YTD
- -19.27%
- 6M
- -2.76%
- 1Y
- 274.34%
- 3Y*
- -27.89%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ZURA Monthly Returns History
Based on dividend-adjusted daily data since Sep 3, 2021, ZURA's average daily return is +0.22%, while the average monthly return is +1.66%. At this rate, an investment would double in approximately 3.5 years.
Historically, 55% of months were positive and 45% were negative. The best month was Sep 2025 with a return of +112.3%, while the worst month was Apr 2023 at -54.4%. The longest winning streak lasted 10 consecutive months, and the longest losing streak was 5 months.
On a daily basis, ZURA closed higher 38% of trading days. The best single day was Mar 22, 2023 with a return of +314.4%, while the worst single day was Mar 27, 2023 at -42.8%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 8.40% | 16.55% | -10.12% | -14.62% | -15.35% | -1.63% | -19.27% | ||||||
| 2025 | -24.80% | -27.66% | -5.15% | 19.38% | -34.42% | 3.96% | 33.33% | 45.71% | 112.25% | -11.32% | -0.00% | 36.46% | 109.60% |
| 2024 | -38.97% | 29.12% | -30.16% | 66.15% | 22.95% | -33.33% | 12.86% | 4.56% | -1.69% | 8.37% | -30.68% | -18.03% | -46.47% |
| 2023 | 0.98% | 1.36% | 42.78% | -54.36% | -17.18% | 45.39% | -16.10% | 0.00% | -4.07% | -28.79% | 3.19% | -3.71% | -54.26% |
| 2022 | -0.51% | 0.31% | 0.61% | 0.50% | -0.50% | 0.40% | 0.20% | 0.50% | 0.30% | 0.50% | 0.69% | 0.39% | 3.44% |
| 2021 | 1.13% | 0.10% | 0.20% | -0.20% | 1.23% |
Benchmark Metrics
Zura Bio Limited has an annualized alpha of 68.58%, beta of 0.35, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since September 03, 2021.
- This stock tended to rise when S&P 500 Index fell (downside capture of -29.15%), but participation in market rallies was also limited (-49.26%) - a profile typical of counter-cyclical assets.
- Beta of 0.35 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 68.58%
- Beta
- 0.35
- R²
- 0.00
- Upside Capture
- -49.26%
- Downside Capture
- -29.15%
Return for Risk
Risk / Return Rank
ZURA ranks 92 for risk / return — in the top 92% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Zura Bio Limited (ZURA) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZURA | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.50 | ||
| Sortino ratioReturn per unit of downside risk | +0.85 | ||
| Omega ratioGain probability vs. loss probability | 1.41 | 1.37 | +0.05 |
| Calmar ratioReturn relative to maximum drawdown | 5.34 | 2.78 | +2.56 |
| Martin ratioReturn relative to average drawdown | 13.80 | 12.44 | +1.36 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Zura Bio Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Zura Bio Limited was 97.00%, occurring on May 28, 2025. The portfolio has not yet recovered.
The current Zura Bio Limited drawdown is 87.26%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -97.00%May 2025 | 2y 2mo | — | 3y 3moMar 2023 - now |
2023 bear market2023 | -32.65%Mar 2023 | 1d | 1d | 2dMar 2023 - Mar 2023 |
2023 pullback2023 | -9.09%Mar 2023 | 11d | 3d | 14dMar 2023 - Mar 2023 |
2021 pullback2021 | -1.92%Sep 2021 | 0s | 1d | 1dSep 2021 - Sep 2021 |
2023 pullback2023 | -1.35%Jan 2023 | 1d | 25d | 26dJan 2023 - Feb 2023 |
Drawdown Indicators
| ZURA | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -97.00% | -56.78% | -40.22% |
Max Drawdown (1Y)Largest decline over 1 year | -51.70% | -9.10% | -42.60% |
Max Drawdown (3Y)Largest decline over 3 years | -91.16% | -18.90% | -72.26% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -87.26% | -1.80% | -85.46% |
Average DrawdownAverage peak-to-trough decline | -59.10% | -10.71% | -48.39% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.98% | 2.03% | +17.95% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Zura Bio Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Zura Bio Limited is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ZURA in comparison with other companies in the Biotechnology industry. Currently, ZURA has a P/B value of 2.2. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZURA
Add Zura Bio Limited to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZURA